Gambaran Kepatuhan Penggunaan Obat Antituberkulosis pada Pasien Tuberkulosis Paru di Puskesmas Pahandut Kota Palangkaraya

https://doi.org/10.22146/jmpf.83777

Anna Singgih D.P. Priyaputranti(1), Fita Rahmawati(2*), Nanang Munif Yasin(3)

(1) *) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta *) Puskesmas Pahandut. Kota Palangkaraya
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Tuberculosis is a communicable disease caused by Mycobacterium tuberculosis. Indonesia's health profile stated that the number of tuberculosis cases in 2021 was 397,377 cases, indicating an increase compared to 2020 of 351,936 cases. Medication adherence is crucial for the management of tuberculosis. Some failures of tuberculosis treatment are caused by non-adherence. Detection of medication adherence is important to help control tuberculosis. This study aimed to describe the medication adherence of antituberculosis drugs and the predictive factor among pulmonary tuberculosis of drug-susceptible tuberculosis. This study uses a cross-sectional design with retrospective data collection. Drug therapy monitoring and TB-01 form collected non-adherence identification from January to February 2023 at Puskesmas Pahandut, Palangkaraya city, which involved 35 patients. The predictive factor was identified by an interview with the patient, the treatment observers, and the chief tuberculosis programmer. Adherence was measured by medication left over at the visit. The results showed 24 (77%)  adherent patients and 8 (23%)  non-adherent patients. The predictive factor involved seven dimensions patient-centered (lack of motivation, forgetting to take medicine, unacknowledged information by public health care provider, confusion about how to take medicine), access factors, social and lack of role of the treatment observers. The improvement role of healthcare providers in public health centers and treatment observers is prominent in increasing patient adherence. 


Keywords


tuberkulosis; puskesmas; kepatuhan

Full Text:

PDF


References

  1. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. TBC Indonesia. Published 2020. Accessed March 29, 2022. https://tbindonesia.or.id/pustaka/pedoman/umum/pedoman-nasional-pelayanan-kedokteran-tata-laksana-tuberkulosis/
  2. World Health Organization. Treatment of tuberculosis: guidelines. Published online 2010. Accessed March 29, 2022. https://apps.who.int/iris/handle/10665/44165
  3. WHO. WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB. Published 2021. Accessed September 21, 2022. https://www.who.int/news/item/17-06-2021-who-releases-new-global-lists-of-high-burden-countries-for-tb-hiv-associated-tb-and-drug-resistant-tb
  4. Kementerian Kesehatan Republik Indonesia. Dashboard TB. TBC Indonesia. Published 2022. Accessed September 10, 2022. https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/
  5. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376
  6. WHO. Anti-tuberculosis drug resistance in the world : fourth global report. Published online 2008. https://apps.who.int/iris/bitstream/handle/10665/43889/WHO_HTM_TB_2008.394_eng.pdf;jsessionid=C97EFEF0D5A237BF4274955EC07A7B9A?sequence=1
  7. Pameswari P, Halim A, Yustika L. Tingkat Kepatuhan Penggunaan Obat pada Pasien Tuberkulosis di Rumah Sakit Mayjen H. A Thalib Kabupaten Kerinci. Jurnal Sains Farmasi & Klinis. 2016;2(2):undefined-undefined. doi:10.29208/jsfk.2016.2.2.60
  8. Juan G, Lloret T, Perez C, et al. Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. The International Journal of Tuberculosis and Lung Disease. 2006;10(2):215-221.
  9. Sriwijaya RA, Kumala S, Keban SA. Pengaruh Edukasi Farmasis terhadap Outcome Terapi Pasien TB Paru Fase Intensif di RSUP Persahabatan Periode Maret-Juli 2015. Jurnal Penelitian Sains. 2019;20(3):86-91. doi:10.26554/jps.v20i3.514
  10. Ditjen P2P Kemkes RI. Profil Kesehatan Indonesia 2021. Kemenkes RI; 2022.
  11. Kementerian Kesehatan Republik Indonesia. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) | Badan Penelitian dan Pengembangan Kesehatan. Published 2018. Accessed March 28, 2022. https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/
  12. Amran R, Abdulkadir W, Madania M. Tingkat Kepatuhan Penggunaan Obat Anti Tuberkulosis Pada Pasien Di Puskesmas Tombulilato Kabupaten Bone Bolango. Indonesian Journal of Pharmaceutical Education. 2021;1(1):57-66. doi:10.37311/ijpe.v1i1.10123
  13. Ahdiyah NN, Andriani M, Andriani L. Tingkat Kepatuhan Penggunaan Obat Anti Tuberkulosis Pada Pasien TB Paru Dewasa Di Puskesmas Putri Ayu. Lumbung Farmasi: Jurnal Ilmu Kefarmasian. 2022;3(1):23-28. doi:10.31764/lf.v3i1.6817
  14. Ngamelubun GS, Widani NL, Surianto F. Gambaran Kepatuhan Pasien Tuberkulosis Dalam Meminum Obat Di Balai Kesehatan Paru Masyarakat Provinsi Maluku. Carolus Journal of Nursing. 2022;5(1):78-86. doi:10.37480/cjon.v5i1.123
  15. Kementerian Kesehatan Republik Indonesia. Permenkes No. 43 Tahun 2019 tentang Pusat Kesehatan Masyarakat. Published 2019. Accessed March 22, 2023. https://peraturan.bpk.go.id/Home/Details/138635/permenkes-no-43-tahun-2019
  16. Dinas Kesehatan Kota Palangkaraya. Profil TB DInas Kesehatan Kota Palangka Raya Tahun 2021. Published online 2021.
  17. Berndt AE. Sampling Methods. J Hum Lact. 2020;36(2):224-226. doi:10.1177/0890334420906850
  18. Johnson JL, Adkins D, Chauvin S. A Review of the Quality Indicators of Rigor in Qualitative Research. Am J Pharm Educ. 2020;84(1):7120. doi:10.5688/ajpe7120
  19. Goruntla N, Kolisetty J, Moses K, et al. Impact Of Pharmacist Counselling On Knowledge, And Medication Adherence In Tuberculosis Patients: A Quasi-Experimental Design. Published online December 3, 2020. doi:10.22376/ijpbs/lpr.2020.10.5.P6-10
  20. BPOM. Modul Farmakovigilans Untuk Tenaga Profesional Kesehatan Proyek “Ensuring Drug and Food Safety.” Badan Pengawasan Obat dan Makanan; 2020.
  21. Nasution, L. M. View of Statistik Deskriptif. Published 2020. Accessed March 23, 2023. http://e-jurnal.staisumatera-medan.ac.id/index.php/hikmah/article/view/16/13
  22. Agustian, Dias M, Masria S. Hubungan Usia, Jenis Kelamin dan Tingkat Pendidikan dengan Kejadian TB Paru di Wilayah Kerja Puskesmas Cibadak Kabupaten Sukabumi. Bandung Conference Series: Medical Science. 2022;2(1):1120-1125. doi:10.29313/bcsms.v2i1.2256
  23. Andayani S. Prediksi Kejadian Penyakit Tuberkulosis Paru Berdasarkan Jenis Kelamin. Jurnal Keperawatan Muhammadiyah Bengkulu. 2020;8(2):135-140. doi:10.36085/jkmb.v8i2.1063
  24. Sharma N, Khanna A, Chandra S, et al. Partnership in tuberculosis control through involvement of pharmacists in Delhi: An exploratory operational research study. Indian J Pharmacol. 2019;51(3):168-172. doi:10.4103/ijp.IJP_300_18
  25. Nurjana MA. Faktor Risiko Terjadinya Tuberculosis Paru Usia Produktif (15-49 Tahun) di Indonesia. Media Penelitian dan Pengembangan Kesehatan. 2015;25(3):163-170. doi:10.22435/mpk.v25i3.4387.163-170
  26. Kementerian Kesehatan Republik Indonesia. PMK Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. Published online 2016.
  27. WHO. Global Tuberculosis Reports 2022. Published 2022. Accessed March 29, 2022. https://www.who.int/teams/control-of-neglected-tropical-diseases/lymphatic-filariasis/morbidity-management-and-disability-prevention/global-tuberculosis-programme
  28. PB. PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2021. Published April 9, 2021. Accessed March 24, 2023. https://pbperkeni.or.id/unduhan
  29. Firdaus A, Pratama GC, Andarini MY. Scoping Review: Hubungan Kadar HbA1c terhadap Pasien Diabetes Melitus dengan Tuberkulosis. Prosiding Pendidikan Dokter. 2021;7(1):77-84. doi:10.29313/kedokteran.v7i1.26341
  30. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLOS ONE. 2017;12(11):e0187967. doi:10.1371/journal.pone.0187967
  31. Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39(1):149-155. doi:10.1093/ije/dyp308
  32. Endalkachew K, Ferede YM, Derso T, Kebede A. Prevalence and associated factors of undernutrition among adult TB patients attending Amhara National Regional State hospitals, Northwest Ethiopia. J Clin Tuberc Other Mycobact Dis. 2021;26:100291. doi:10.1016/j.jctube.2021.100291
  33. Choi H, Yoo JE, Han K, et al. Body Mass Index, Diabetes, and Risk of Tuberculosis: A Retrospective Cohort Study. Front Nutr. 2021;8:739766. doi:10.3389/fnut.2021.739766
  34. Prince L, Andrews JR, Basu S, Goldhaber-Fiebert JD. Risk of self-reported symptoms or diagnosis of active tuberculosis in relationship to low body mass index, diabetes and their co-occurrence. Tropical Medicine & International Health. 2016;21(10):1272-1281. doi:10.1111/tmi.12763
  35. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opinion on Drug Safety. 2006;5(2):231-249. doi:10.1517/14740338.5.2.231
  36. Abbas A. Monitoring Efek Samping Obat Anti-Tuberkulosis (OAT) Pada Pengobatan Tahap Intensif Penderita TB Paru Di Kota Makassar. Published online 2017.
  37. Dasopang ES, Hasanah F, Nisak C. Analisis Deskriptif Efek Samping Penggunaan Obat Anti Tuberculosis Pada Pasien Tbc Di Rsud Dr. Pirngadi Medan. Jurnal Penelitian Farmasi & Herbal. 2019;2(1):44-49. doi:10.36656/jpfh.v2i1.180
  38. Sari ID, Yuniar Y, Syaripuddin M. Studi Monitoring Efek Samping Obat Antituberkulosis FDC Kategori 1 Di Provinsi Banten dan Provinsi Jawa Barat. Media Penelitian dan Pengembangan Kesehatan. 2014;24(1):28-35. doi:10.22435/mpk.v24i1.3484.28-35
  39. Chang KC, Leung CC, Tam CM. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis. 2004;8(12):1492-1498.
  40. Bea S, Lee H, Kim JH, et al. Adherence and Associated Factors of Treatment Regimen in Drug-Susceptible Tuberculosis Patients. Frontiers in Pharmacology. 2021;12. Accessed September 7, 2022. https://www.frontiersin.org/articles/10.3389/fphar.2021.625078
  41. Woimo TT, Yimer WK, Bati T, Gesesew HA. The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study. BMC Public Health. 2017;17(1):269. doi:10.1186/s12889-017-4188-9
  42. Fitri LD. Kepatuhan Minum Obat pada Pasien Tuberkulosis Paru. Jurnal Ilmu Kesehatan Masyarakat. 2018;7(01):33-42. doi:10.33221/jikm.v7i01.50
  43. Al-Shaer MH, Elewa H, Alkabab Y, Nazer LH, Heysell SK. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. BMC Infect Dis. 2018;18(1):384. doi:10.1186/s12879-018-3309-0
  44. WHO. Treatment of Tuberculosis: Guidelines – 4th Ed. WHO; 2010.
  45. Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. Int J Environ Res Public Health. 2020;17(15):5626. doi:10.3390/ijerph17155626
  46. Kiros YK, Teklu T, Desalegn F, Tesfay M, Klinkenberg E, Mulugeta A. Adherence to anti-tuberculosis treatment in Tigray, Northern Ethiopia. Public Health Action. 2014;4(Suppl 3):S31-S36. doi:10.5588/pha.14.0054
  47. Nezenega ZS, Gacho YHM, Tafere TE. Patient satisfaction on tuberculosis treatment service and adherence to treatment in public health facilities of Sidama zone, South Ethiopia. BMC Health Serv Res. 2013;13:110. doi:10.1186/1472-6963-13-110
  48. Getahun B, Nkosi ZZ. Is directly observed tuberculosis treatment strategy patient-centered? A mixed method study in Addis Ababa, Ethiopia. PLoS One. 2017;12(8):e0181205. doi:10.1371/journal.pone.0181205
  49. Tadesse T, Demissie M, Berhane Y, Kebede Y, Abebe M. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424. doi:10.1186/1471-2458-13-424
  50. Ayele AA, Asrade Atnafie S, Balcha DD, et al. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia. Patient Prefer Adherence. 2017;11:743-749. doi:10.2147/PPA.S131314
  51. Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis Treatment Non-Adherence and Lost to Follow Up among TB Patients with or without HIV in Developing Countries: A Systematic Review. Iran J Public Health. 2015;44(1):1-11.
  52. Kebede A, Wabe NT. Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South west ethiopia. N Am J Med Sci. 2012;4(2):67-71. doi:10.4103/1947-2714.93376
  53. Sondang B, Asrifuddin* A, Kaunang WPJ. Analisis Peran Pengawas Menelan Obat (PMO) Terhadap Kepatuhan Menelan Obat Anti Tuberkulosis Pada Penderita Tuberkulosis Paru Di Puskesmas Kauditan Kabupaten Minahasa Utara. Jurnal KESMAS, Vol 10, No 4, April 2021. Published online 2021.



DOI: https://doi.org/10.22146/jmpf.83777

Article Metrics

Abstract views : 3577 | views : 5339

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats